AU2018304242B2 - Methods for detection of plasma cell dyscrasia - Google Patents

Methods for detection of plasma cell dyscrasia Download PDF

Info

Publication number
AU2018304242B2
AU2018304242B2 AU2018304242A AU2018304242A AU2018304242B2 AU 2018304242 B2 AU2018304242 B2 AU 2018304242B2 AU 2018304242 A AU2018304242 A AU 2018304242A AU 2018304242 A AU2018304242 A AU 2018304242A AU 2018304242 B2 AU2018304242 B2 AU 2018304242B2
Authority
AU
Australia
Prior art keywords
splice variants
expression level
subject
biomarkers
plasma cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018304242A
Other languages
English (en)
Other versions
AU2018304242A1 (en
Inventor
Ignat Drozdov
Mark Kidd
Irvin Mark MODLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquid Biopsy Research LLC
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of AU2018304242A1 publication Critical patent/AU2018304242A1/en
Application granted granted Critical
Publication of AU2018304242B2 publication Critical patent/AU2018304242B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018304242A 2017-07-21 2018-07-18 Methods for detection of plasma cell dyscrasia Active AU2018304242B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
US62/535,419 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (2)

Publication Number Publication Date
AU2018304242A1 AU2018304242A1 (en) 2020-01-16
AU2018304242B2 true AU2018304242B2 (en) 2023-04-27

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018304242A Active AU2018304242B2 (en) 2017-07-21 2018-07-18 Methods for detection of plasma cell dyscrasia

Country Status (14)

Country Link
US (2) US20190025311A1 (enExample)
EP (1) EP3655553B1 (enExample)
JP (1) JP7223741B2 (enExample)
KR (1) KR102785072B1 (enExample)
CN (1) CN111194356B (enExample)
AU (1) AU2018304242B2 (enExample)
BR (1) BR112020000791A2 (enExample)
CA (1) CA3067730A1 (enExample)
DK (1) DK3655553T3 (enExample)
ES (1) ES2916450T3 (enExample)
IL (1) IL271465B2 (enExample)
MX (1) MX2020000785A (enExample)
PL (1) PL3655553T3 (enExample)
WO (1) WO2019018540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas
US20210108259A1 (en) 2019-10-10 2021-04-15 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
US20230203587A1 (en) * 2020-05-29 2023-06-29 Exosome Diagnostics, Inc. Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668659B2 (en) * 2001-11-07 2010-02-23 The Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
CA3002661C (en) * 2004-05-21 2022-03-15 The Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
US20120015906A1 (en) * 2009-01-02 2012-01-19 Shaughnessy Jr John D Uses of bortezomib in predicting survival in multiple myeloma patients
ES2916450T3 (es) 2017-07-21 2022-07-01 Liquid Biopsy Res Llc Método para la detección de discrasia de células plasmáticas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668659B2 (en) * 2001-11-07 2010-02-23 The Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma

Also Published As

Publication number Publication date
KR20200029528A (ko) 2020-03-18
DK3655553T3 (da) 2022-06-20
WO2019018540A1 (en) 2019-01-24
US12366575B2 (en) 2025-07-22
US20190025311A1 (en) 2019-01-24
US20230022417A1 (en) 2023-01-26
IL271465B1 (en) 2023-04-01
PL3655553T3 (pl) 2022-09-26
BR112020000791A2 (pt) 2020-07-21
KR102785072B1 (ko) 2025-03-20
CA3067730A1 (en) 2019-01-24
EP3655553A1 (en) 2020-05-27
IL271465A (en) 2020-01-30
JP2020528274A (ja) 2020-09-24
ES2916450T3 (es) 2022-07-01
CN111194356B (zh) 2024-04-23
JP7223741B2 (ja) 2023-02-16
AU2018304242A1 (en) 2020-01-16
CN111194356A (zh) 2020-05-22
EP3655553B1 (en) 2022-03-23
MX2020000785A (es) 2020-11-06
IL271465B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US12366575B2 (en) Chemical compositions and methods of use
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
US12399179B2 (en) Chemical compositions and methods of use
JP2003259877A (ja) 肝線維症疾患マーカーおよびその利用
KR20100037637A (ko) Ｅｇｆｒ 억제제 치료에 대한 예측 마커
KR20190126812A (ko) 질환 진단용 바이오마커
CN100516876C (zh) 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
KR102001153B1 (ko) 유방암 예후 예측용 조성물 및 방법
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
KR101804678B1 (ko) Bis 억제제 스크리닝용 마커, 이를 포함하는 스크리닝 키트 및 이를 이용한 bis 억제제 스크리닝 방법
KR20240042611A (ko) 알파-n-아세틸갈락토사미나이드 알파-2,6-시알릴전이효소 5 (st6galnac5) 억제제를 이용한 인지 장애 치료
HK1084696A (en) Prognostic for hematological malignancy
HK1141723A (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin
KR20130024134A (ko) Ｇｃｐｓ 증후군 진단용 마이크로어레이 및 키트

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)